Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms
Identifieur interne : 002812 ( Main/Exploration ); précédent : 002811; suivant : 002813Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms
Auteurs : I. B. Boehm [États-Unis] ; G. A. Boehm [Royaume-Uni] ; R. Bauer [États-Unis]Source :
- Rheumatology International [ 0172-8172 ] ; 1998-08-01.
English descriptors
Abstract
Abstract: There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received weekly administrations of 10–25 mg methotrexate (MTX). Previous treatment with antimalarials and/or glucocorticosteroids was not effective or had to be withdrawn because of side effects. Of 12 patients, ten showed improvement of their skin lesions; two patients did not respond to low-dose MTX; two patients cleared rapidly, and five other patients had long-lasting remissions of 5–24 months after stopping MTX treatment. A reduction of circulating autoantibodies was detected in five patients. In all patients, MTX was well tolerated subjectively and objectively. Weekly low-dose MTX is useful for the treatment of cutaneous LE, particularly in those cases which need long-term treatment and/or do not respond to standard therapeutic regimens.
Url:
DOI: 10.1007/s002960050058
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000892
- to stream Istex, to step Curation: 000892
- to stream Istex, to step Checkpoint: 001616
- to stream Main, to step Merge: 002854
- to stream Main, to step Curation: 002812
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms</title><author><name sortKey="Boehm, I B" sort="Boehm, I B" uniqKey="Boehm I" first="I. B." last="Boehm">I. B. Boehm</name></author><author><name sortKey="Boehm, G A" sort="Boehm, G A" uniqKey="Boehm G" first="G. A." last="Boehm">G. A. Boehm</name></author><author><name sortKey="Bauer, R" sort="Bauer, R" uniqKey="Bauer R" first="R." last="Bauer">R. Bauer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7527882C3DD27BC4445614A8AF8D59959EF7DAB0</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1007/s002960050058</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-1DD6P8W2-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000892</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000892</idno><idno type="wicri:Area/Istex/Curation">000892</idno><idno type="wicri:Area/Istex/Checkpoint">001616</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001616</idno><idno type="wicri:doubleKey">0172-8172:1998:Boehm I:management:of:cutaneous</idno><idno type="wicri:Area/Main/Merge">002854</idno><idno type="wicri:Area/Main/Curation">002812</idno><idno type="wicri:Area/Main/Exploration">002812</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms</title><author><name sortKey="Boehm, I B" sort="Boehm, I B" uniqKey="Boehm I" first="I. B." last="Boehm">I. B. Boehm</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Delaware</region></placeName><wicri:cityArea>Department of Dermatology, University of Bonn, Sigmund-Freud Strasse 25, D-53105 Bonn, Germany Fax: 49-228-2874333</wicri:cityArea></affiliation></author><author><name sortKey="Boehm, G A" sort="Boehm, G A" uniqKey="Boehm G" first="G. A." last="Boehm">G. A. Boehm</name><affiliation wicri:level="4"><orgName type="university">Université d'Édimbourg</orgName><country>Royaume-Uni</country><placeName><settlement type="city">Édimbourg</settlement><region type="country">Écosse</region></placeName></affiliation></author><author><name sortKey="Bauer, R" sort="Bauer, R" uniqKey="Bauer R" first="R." last="Bauer">R. Bauer</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Delaware</region></placeName><wicri:cityArea>Department of Dermatology, University of Bonn, Sigmund-Freud Strasse 25, 53105 Bonn, Germany</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Rheumatology International</title><title level="j" type="sub">Clinical and Experimental Investigations</title><title level="j" type="abbrev">Rheumatology International</title><idno type="ISSN">0172-8172</idno><idno type="eISSN">1437-160X</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>Berlin/Heidelberg</pubPlace><date type="published" when="1998-08-01">1998-08-01</date><biblScope unit="volume">18</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="59">59</biblScope><biblScope unit="page" to="62">62</biblScope></imprint><idno type="ISSN">0172-8172</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0172-8172</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Immunomodulatory activity</term><term>Key words Cutaneous lupus erythematosus</term><term>Low-dose methotrexate</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: There is no consensus about an effective and safe treatment for patients with cutaneous lupus erythematosus (LE) who are refractory to antimalarials and/or low-dose oral glucocorticosteroids. Therefore, we retrospectively analyzed the clinical data and laboratory findings of 12 patients who received weekly administrations of 10–25 mg methotrexate (MTX). Previous treatment with antimalarials and/or glucocorticosteroids was not effective or had to be withdrawn because of side effects. Of 12 patients, ten showed improvement of their skin lesions; two patients did not respond to low-dose MTX; two patients cleared rapidly, and five other patients had long-lasting remissions of 5–24 months after stopping MTX treatment. A reduction of circulating autoantibodies was detected in five patients. In all patients, MTX was well tolerated subjectively and objectively. Weekly low-dose MTX is useful for the treatment of cutaneous LE, particularly in those cases which need long-term treatment and/or do not respond to standard therapeutic regimens.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Delaware</li><li>Écosse</li></region><settlement><li>Édimbourg</li></settlement><orgName><li>Université d'Édimbourg</li></orgName></list><tree><country name="États-Unis"><region name="Delaware"><name sortKey="Boehm, I B" sort="Boehm, I B" uniqKey="Boehm I" first="I. B." last="Boehm">I. B. Boehm</name></region><name sortKey="Bauer, R" sort="Bauer, R" uniqKey="Bauer R" first="R." last="Bauer">R. Bauer</name></country><country name="Royaume-Uni"><region name="Écosse"><name sortKey="Boehm, G A" sort="Boehm, G A" uniqKey="Boehm G" first="G. A." last="Boehm">G. A. Boehm</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002812 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002812 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7527882C3DD27BC4445614A8AF8D59959EF7DAB0
|texte= Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechanisms
}}
| This area was generated with Dilib version V0.6.33. |  |